GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Evolva Holding SA en liquidation (OTCPK:ELVYY) » Definitions » Capex-to-Operating-Income

Evolva Holding en liquidation (Evolva Holding en liquidation) Capex-to-Operating-Income : 0.00 (As of Jun. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Evolva Holding en liquidation Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Evolva Holding en liquidation's Capital Expenditure for the six months ended in Jun. 2023 was $-2.29 Mil. Its Operating Income for the six months ended in Jun. 2023 was $-40.24 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.


Evolva Holding en liquidation Capex-to-Operating-Income Historical Data

The historical data trend for Evolva Holding en liquidation's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evolva Holding en liquidation Capex-to-Operating-Income Chart

Evolva Holding en liquidation Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Capex-to-Operating-Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Evolva Holding en liquidation Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Evolva Holding en liquidation's Capex-to-Operating-Income

For the Biotechnology subindustry, Evolva Holding en liquidation's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Evolva Holding en liquidation's Capex-to-Operating-Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Evolva Holding en liquidation's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Evolva Holding en liquidation's Capex-to-Operating-Income falls into.



Evolva Holding en liquidation Capex-to-Operating-Income Calculation

Evolva Holding en liquidation's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2022 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-2.418) / -43.363
=N/A

Evolva Holding en liquidation's Capex-to-Operating-Income for the quarter that ended in Jun. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-2.293) / -40.244
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Evolva Holding en liquidation  (OTCPK:ELVYY) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


Evolva Holding en liquidation Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Evolva Holding en liquidation's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Evolva Holding en liquidation (Evolva Holding en liquidation) Business Description

Traded in Other Exchanges
Address
Duggingerstrasse 23, Reinach, CHE, CH-4153
Evolva Holding SA en liquidation formerly Evolva Holding SA is a biotechnology company. The company is engaged in discovering, developing, and commercializing ingredients and biomanufacturing processes for nutrition, healthcare, and wellness products. Geographically, the company operates in Switzerland and the United States where Switzerland derives a majority of its revenue.

Evolva Holding en liquidation (Evolva Holding en liquidation) Headlines

From GuruFocus

Half Year 2023 Evolva Holding SA Earnings Call Transcript

By GuruFocus Research 02-13-2024